scd25  (R&D Systems)

Journal: Frontiers in Neurology

Article Title: A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis

doi: 10.3389/fneur.2024.1415106

Figure Lengend Snippet: Treg numbers and suppressive function increased with CTLA4-Ig/IL-2 treatment throughout the 48-week treatment period. Changes in Treg suppressive function (A) , the percentage of CD4 + CD25 + FOXP3 + cells (B) , the percentage of CD4 + CD25 + cells (C) , the percentage of CD4 + CD25 − cells (D) , and the percentage of CD8 + cells (E) throughout the study are shown. Changes in CD25 protein expression (F) and FOXP3 protein expression (G) in the CD4 + CD25 + FOXP3 + population by mean fluorescent intensity (MFI) throughout the study are shown. Data were analyzed by a one-way ANOVA with post-hoc Tukey test and p values less than 0.05 were considered significant. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01.

Article Snippet: Levels of soluble CD25 (sCD25) were also assayed by ELISA (R&D Systems, Cat# DR2A00) using sera from participants ( n = 4) and healthy controls ( n = 23) according to the manufacturer’s instructions.

Techniques: Expressing

Journal: The Journal of Clinical Investigation

Article Title: The SWI/SNF chromatin-remodeling subunit DPF2 facilitates NRF2-dependent antiinflammatory and antioxidant gene expression

doi: 10.1172/JCI158419

Figure Lengend Snippet: ( A ) Representative images of Vav1-Cre –derived 28-day-old mice. ( B ) Total BWs of 28-day-old mice. ( C ) Kaplan-Meier survival curves; the median survival of Dpf2 Δ/Δ mice was 28 days. ( D ) Representative images of organs from 28-day-old mice. ( E ) Total number of cells in BM, spleen, and thymus. ( F ) CBC of PB in approximately 28-day-old mice ( n = 18). Hb, hemoglobin; PLT, platelets. ( G ) Representative H&E staining of BM, spleen, and thymus from 28-day-old mice. Scale bars: 50 μm. ( H and I ) Representative H&E staining of liver ( G ) and lung ( H ) from end-stage Dpf2 Δ/Δ and age-matched Dpf2 fl/fl mice. Scale bars: 200 μm. ( J ) Representative CD68/macrosialin IHC staining of lung and liver. Scale bars: 200 μm (lung IHC), 50 μm ( Dpf2 fl/fl liver), and 100 μm ( Dpf2 Δ/Δ liver). ( K ) Representative CD69 IHC staining of lung and liver infiltrates. Scale bars: 50 μm. ( L ) Plasma cytokine levels. Values correspond to the mean spot pixel density relative to background from 4 mice/genotype. ( M ) Chemistry profiling of PB from 28-day-old mice ( n = 3). ( N ) Serum ferritin and sCD25 plasma levels. All bar graph data represent the mean ± SD. *** P < 0.001, by 2-tailed, unpaired Student’s t test ( B , M , and N ) and ordinary, 1-way ANOVA ( E and F ).

Article Snippet: Plasma was used for the cytokine array analyses (R&D Systems, ARY028); the ferritin ELISA kit (ALPCO, 41-FERMS-E01); the sCD25 ELISA kit (G-Biosciences, IT5809); and chemistry profiling (HESKA; catalog 6330, COMP/EWRAP).

Techniques: Derivative Assay, Staining, Immunohistochemistry, Clinical Proteomics

Journal: The Journal of Clinical Investigation

Article Title: The SWI/SNF chromatin-remodeling subunit DPF2 facilitates NRF2-dependent antiinflammatory and antioxidant gene expression

doi: 10.1172/JCI158419

Figure Lengend Snippet: ( A ) Kaplan-Meier survival curves of mice treated with vehicle or CDDO-Im. Treatment was interrupted after 85 days (dashed line). A log-rank (Mantel-Cox) text was performed to determine significant differences in the survival of Dpf2 Δ/Δ mice treated with vehicle or CDDO-Im. ( B and C ) Expression of Dpf2 and Nrf2 ( B ), and NRF2 target genes ( C ) in LK cells from Dpf2 fl/fl and Dpf2 Δ/Δ mice treated with vehicle or CDDO-Im. P value for vehicle-treated versus CDDO-Im–treated Dpf2 Δ/Δ mouse data are indicated below each plot. ( D ) sCD25 in plasma from the indicated groups of mice. ( E ) PB counts in mice treated for 2 weeks with vehicle or CDDO-Im. ( F ) Flow cytometric analyses of splenic cell populations. Data represent the mean ± SEM. P values were calculated using 2-way ANOVA.

Article Snippet: Plasma was used for the cytokine array analyses (R&D Systems, ARY028); the ferritin ELISA kit (ALPCO, 41-FERMS-E01); the sCD25 ELISA kit (G-Biosciences, IT5809); and chemistry profiling (HESKA; catalog 6330, COMP/EWRAP).

Techniques: Expressing, Clinical Proteomics

Journal: Mediterranean Journal of Hematology and Infectious Diseases

Article Title: Soluble ST2 and CD163 as Potential Biomarkers to Differentiate Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

doi: 10.4084/MJHID.2019.008

Figure Lengend Snippet: Characteristics of the enrolled patients (All values are presented as median and range or mean ± SD).

Article Snippet: The expression of Human serum sST2 (R&D, CAT# DST200), sCD163 (R&D, CAT# DC163) and Human sCD25/IL-2R (Diaclone, CAT#850.500.096) were measured using ELISA.

Techniques: Activity Assay

Journal: Mediterranean Journal of Hematology and Infectious Diseases

Article Title: Soluble ST2 and CD163 as Potential Biomarkers to Differentiate Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

doi: 10.4084/MJHID.2019.008

Figure Lengend Snippet: Serum levels of sCD25 in pHLH, MAS patients and control group. Serum levels of sCD25 in pHLH, MAS patients before treatment and control group. Serum levels of sCD25 in pHLH before and after treatment. Serum levels of sCD25 in MAS before and after treatment. The horizontal line represents the quartile and the median. ns: not significant; * P<0.05; *** P<0.001.

Article Snippet: The expression of Human serum sST2 (R&D, CAT# DST200), sCD163 (R&D, CAT# DC163) and Human sCD25/IL-2R (Diaclone, CAT#850.500.096) were measured using ELISA.

Techniques: